Sex: M
Vaccine: COVID19
Symptoms: Body mass index, Brain natriuretic peptide, Computerised tomogram thorax, Echocardiogram, Ejection fraction
Clinical narrative: Pulmonary Hypertension; flu-like symptoms; This is a literature report.  A 49-year-old male patient received BNT162b2 (BNT162B2), in Jan2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "non-smoker" (ongoing); "mild exercise-induced asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Albuterol for mild exercise-induced asthma. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Dec2020, for COVID-19 immunisation. The following information was reported: PULMONARY HYPERTENSION (medically significant, life threatening) with onset 2021, 3 weeks after the suspect product(s) administration, outcome "recovering"; INFLUENZA LIKE ILLNESS (medically significant) with onset 2021, 3 weeks after the suspect product(s) administration, outcome "recovering", described as "flu-like symptoms". The patient underwent the following laboratory tests and procedures: Body mass index: (unspecified date) 23; Brain natriuretic peptide (normal high range 900): (unspecified date) 22 pg/mL; Computerised tomogram thorax: (unspecified date) with 3D reconstruction of the PA tree was normal w, notes: evidence of pulmonary clots; Echocardiogram: (unspecified date) showed no worsening, notes: of RVSP and continued normal RV function; (unspecified date) revealed normal left ventricular function with an, notes: ejection fraction (EF) of 65%, normal right ventricular size and function; Ejection fraction: (unspecified date) 65 %; Haematocrit: (unspecified date) 50 %; maximal tricuspid regurgitation velocity: (16Feb2021) 3.09, notes: Units: m/s; (24Feb2021) 3.1, notes: Units: m/s; (18Mar2021) 3.0, notes: Units: m/s; (21Apr2021) 2.9, notes: Units: m/s; (17Jun2021) 3.1, notes: Units: m/s; (15Feb2022) 3.2, notes: Units: m/s; Low density lipoprotein: (unspecified date) elevated; NYHA classification: (unspecified date) 3-4; (unspecified date) 1-2, notes: over one year; Oxygen saturation: (unspecified date) 92 %; (unspecified date) 98-100 %; Right ventricular systolic pressure: (16Feb2021) 42 mmHg; (24Feb2021) 42 mmHg; (18Mar2021) 39 mmHg; (21Apr2021) 38 mmHg; (17Jun2021) 42 mmHg; (15Feb2022) 45 mmHg; SARS-CoV-2 test: (unspecified date) Negative, notes: at the time of the onset of these symptoms.; Sender's Comments: Based on the information available, a possible contributory role of the suspect drug for the reported events Pulmonary hypertension and Influenza like illness cannot be excluded. This impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202300293682 Same article/ drug/event and different patient;